Evidence map›Paper›PMID 39792034›Full record

ArticleACS nano2025

Substructure-Specific Antibodies Against Fentanyl Derivatives.

Asheley Chapman, Minghao Xu, Michelle Schroeder, Jason M Goldstein, Asiya Chida, Joo R Lee, Xiaoling Tang, Rebekah E Wharton, M G Finn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asheley ChapmanSchool of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.
Minghao XuSchool of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.
Michelle SchroederSchool of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.
Jason M GoldsteinImmunodiagnostic Development Team, Preparedness, Response, & Outbreak Services Branch, Division of Core Laboratory Services & Response, Office of Laboratory Systems and Response, Centers for Disease Control and Prevention, 1600 Clifton Rd NE., Atlanta, Georgia 30333, United States.
Asiya ChidaImmunodiagnostic Development Team, Preparedness, Response, & Outbreak Services Branch, Division of Core Laboratory Services & Response, Office of Laboratory Systems and Response, Centers for Disease Control and Prevention, 1600 Clifton Rd NE., Atlanta, Georgia 30333, United States.
Joo R LeeImmunodiagnostic Development Team, Preparedness, Response, & Outbreak Services Branch, Division of Core Laboratory Services & Response, Office of Laboratory Systems and Response, Centers for Disease Control and Prevention, 1600 Clifton Rd NE., Atlanta, Georgia 30333, United States.
Xiaoling TangImmunodiagnostic Development Team, Preparedness, Response, & Outbreak Services Branch, Division of Core Laboratory Services & Response, Office of Laboratory Systems and Response, Centers for Disease Control and Prevention, 1600 Clifton Rd NE., Atlanta, Georgia 30333, United States.
Rebekah E WhartonDivision of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, Georgia 30341, United States.ORCID 0000-0003-3027-3811
M G FinnSchool of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.ORCID 0000-0001-8247-3108

Funding

Development of the Next Generation of Conjugate VaccinesR01AI139748 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI TEYTON, LUC · 2018 to 2021
$3.4M
Strategies for generating high affinity antibodies against Gram negative bacteriaR21AI152528 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI FINN, M.G. · 2020 to 2021
$440k
NIAID NIH HHS R01 AI139748NIAID NIH HHS R21 AI152528
6 · The paper itself

Abstract

Structural variants of the synthetic opioid fentanyl are a major threat to public health. Following an investigation showing that many derivatives are poorly detected by commercial lateral flow and related assays, we created hapten conjugate vaccines using an immunogenic virus-like particle carrier and eight synthetic fentanyl derivatives designed to mimic the structural features of several of the more dangerous analogues. Immunization of mice elicited strong antihapten humoral responses, allowing the screening of hundreds of hapten-specific hybridomas for binding strength and specificity. A panel of 13 monoclonal IgG antibodies were selected, each showing a different pattern of recognition of fentanyl structural variations, and all proving to be highly efficient at capturing parent fentanyl compounds in competition ELISA experiments. These results provide antibody reagents for assay development as well as a demonstration of the power of the immune system to create binding agents capable of both broad and specific recognition of small-molecule targets.

Indexed as

Antibodies, MonoclonalFentanylAnimalsEnzyme-Linked Immunosorbent AssayHaptensImmunoglobulin GMiceAntibodies, MonoclonalFentanylHaptensImmunoglobulin Gantibodiesdiagnosticsfentanyl derivativesimmune responseimmunizationvirus-like particles

Identifiers

PMID39792034
PMCPMC11781026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.